Haley Collins
Director, Head of Corporate Communications
Replay available
Taysha Gene Therapies, Inc. (TSHA) Q2 2025 Earnings Call
Taysha Gene Therapies, Inc. (NASDAQ: TSHA) Q2 2025 earnings conference call, held 2025-08-12. Replay captured from the company's public earnings webcast.
Hosted by
Featured presenters
Sean Nolan
Chief Executive Officer
Dukumar Nagandran
President and Head of R&D
Dr. Elsa Rosignol
Director of the Integrated Rett Syndrome Clinic at St. Justine in Montreal and Principal Investigator of the Reveal Phase 1-2 Trials
Cameron Alam
Chief Financial Officer
Investor webinar replay
Watch the replay and follow the connected company analysis, news, and investor updates for Taysha Gene Therapies, Inc..
Replay transcript excerpt
WEBVTT 00:00:00.115 -- 00:00:05.320 Ladies and gentlemen, good morning and welcome to Taysha Jean Therapy's second quarter 00:00:05.320 -- 00:00:10.386 2025 earnings conference call. At this time, all participants are in 00:00:10.386 -- 00:00:16.332 listen-only mode. A brief question and answer session will follow the formal presentation. 00:00:16.332 -- 00:00:20.656 If anyone requires operator assistance during the conference, please signal the operator 00:00:20.656 -- 00:00:24.801 by pressing star and zero on your telephone keypad. 00:00:24.801 -- 00:00:28.297 As a reminder, this conference is being recorded. 00:00:28.297 -- 00:00:33.103 It is now my pleasure to introduce your host, Haley Collins, Director, Head of Corporate 00:00:33.103 -- 00:00:36.388 Communications. Please go ahead. 00:00:36.388 -- 00:00:42.035 Thank you. Good morning and welcome to our second quarter 2025 financial results 00:00:42.035 -- 00:00:44.759 and corporate update conference call. 00:00:44.759 -- 00:00:49.385 Earlier today, Tayshia issued a press release announcing financial results for the second 00:00:49.385 -- 00:00:52.169 quarter ended June 30th, 2025. 00:00:52.169 -- 00:00:56.354 A copy of this press release is available on the company's website and through our SEC 00:00:56.354 -- 00:01:02.103 filings. Joining me on today's call are Sean Nolan, Tayshia's Chief Executive Officer, 00:01:02.103 -- 00:01:07.530 Dukumar Nagandran, President and Head of R&D, Cameron Alam, Chief Financial 00:01:07.530 -- 00:01:12.616 Officer, and Dr. Elsa Rosignol, Director of the Integrated Rett Syndrome Clinic at 00:01:12.616 -- 00:01:19.262 St. Justine in Montreal and Principal Investigator of the Reveal Phase 1-2 Trials. 00:01:19.424 -- 00:01:24.210 We will be presenting slides to accompany our prepar...